KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Tax Provisions (2018 - 2026)

Castle Biosciences' Tax Provisions history spans 8 years, with the latest figure at -$382000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 77.6% to -$382000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.4 million, a 261.37% decrease, with the full-year FY2025 number at -$5.4 million, down 261.37% from a year prior.
  • Tax Provisions hit -$382000.0 in Q4 2025 for Castle Biosciences, down from $115000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for CSTL hit a ceiling of $6.0 million in Q3 2024 and a floor of -$4.7 million in Q2 2025.
  • Historically, Tax Provisions has averaged -$321823.5 across 5 years, with a median of $14000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: plummeted 39240.0% in 2022 and later soared 18690.62% in 2024.
  • Tracing CSTL's Tax Provisions over 5 years: stood at -$1.8 million in 2021, then soared by 103.21% to $57000.0 in 2022, then crashed by 31.58% to $39000.0 in 2023, then crashed by 4471.79% to -$1.7 million in 2024, then surged by 77.6% to -$382000.0 in 2025.
  • Business Quant data shows Tax Provisions for CSTL at -$382000.0 in Q4 2025, $115000.0 in Q3 2025, and -$4.7 million in Q2 2025.